MDL 104206 | 1018473-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: MDL 104206
• 英文别名: (3-hydroxy-2-methoxyphenyl)-(1-(2-p-fluorophenylethyl)-piperidin-4-yl)-methanol；MDL 105725；3-[[1-[2-(4-Fluorophenyl)ethyl]piperidin-4-yl]-hydroxymethyl]-2-methoxyphenol
• CAS: 1018473-89-6
• 化学式: C₂₁H₂₆FNO₃
• 分子量: 359.441
• InChiKey: DVDGOKMQDYFKFY-UHFFFAOYSA-N

物化性质

• 沸点：
  522.1±50.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  MDL 104206 、 1-溴-2-氟乙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 MHMZ
  参考文献：
  名称：

  Total synthesis and evaluation of [18F]MHMZ

  摘要：

  Radiochemical labeling of MDL 105725 using the secondary labeling precursor 2-[F-18] fluoroethyltosylate ([F-18] FETos) was carried out in yields of similar to 90% synthesizing [F-18] MHMZ in a speci. c activity of similar to 50 MBq/ nmol with a starting activity of similar to 3 GBq. Overall radiochemical yield including [F-18] FETos synthon synthesis, [F-18] fluoroalkylation and preparing the injectable [ 18 F] MHMZ solution was 42% within a synthesis time of similar to 100 min. The novel compound showed excellent speci. c binding to the 5-HT2A receptor (K-i = 9.0 nM) in vitro and promising in vivo characteristics. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.054
• 作为产物：
  描述：

  (+/-)-α-[2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl]-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanone 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 生成 MDL 104206
  参考文献：
  名称：

  Total synthesis and evaluation of [18F]MHMZ

  摘要：

  Radiochemical labeling of MDL 105725 using the secondary labeling precursor 2-[F-18] fluoroethyltosylate ([F-18] FETos) was carried out in yields of similar to 90% synthesizing [F-18] MHMZ in a speci. c activity of similar to 50 MBq/ nmol with a starting activity of similar to 3 GBq. Overall radiochemical yield including [F-18] FETos synthon synthesis, [F-18] fluoroalkylation and preparing the injectable [ 18 F] MHMZ solution was 42% within a synthesis time of similar to 100 min. The novel compound showed excellent speci. c binding to the 5-HT2A receptor (K-i = 9.0 nM) in vitro and promising in vivo characteristics. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.054

文献信息

• Sulfuric acid mono-[ 3- ( {1- [ 2- (4-fluoro-phenyl ) -ethyl ] -piperidin-4-YL} -hydroxy-methyl) -2-methoxy-phenyl ] ester
  申请人：——

  公开号：US20030087932A1

  公开（公告）日：2003-05-08

  The present invention is directed to sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester, a metabolite of the 5HT 2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)- 1 -[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and a processes for its preparation and its use in the treatment for a number of disease states.

  本发明涉及硫酸单酯-[3-({1-[2-(4-氟苯基)-乙基]-哌啶-4-基}-羟甲基)-2-甲氧基苯基]，这是5HT2A拮抗剂(+)-&agr;-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的代谢产物，以及其制备和用于治疗多种疾病状态的过程。
• Method for the isolation of sulfuric acid mono-[3({1-[2-(4-fluorophenyly)-ethyl]-piperidin-4-yl}-2-methoxy-phenyl}ester
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US20040152900A1

  公开（公告）日：2004-08-05

  The present invention is directed to the method of isolation of sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester, a metabolite of the 5HT 2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.

  本发明涉及一种分离硫酸单酯类的方法，该硫酸单酯类是5HT2A拮抗剂（+）-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的代谢物，化合物名称为硫酸单-[3-(1-【2-(4-氟苯基)乙基】-哌啶-4-基)-羟甲基]-2-甲氧基苯酯。
• SULFURIC ACID MONO-[3-({1-[2-(4-FLUORO-PHENYL)-ETHYL]-PIPERIDIN-4-YL}-HYDROXY-METHYL)-2-METHOXY-PHENYL]ESTER
  申请人：AVENTIS PHARMACEUTICALS INC.

  公开号：EP1202967B1

  公开（公告）日：2006-12-20
• Total synthesis and evaluation of [18F]MHMZ
  作者：Matthias M. Herth、Fabian Debus、Markus Piel、Mikael Palner、Gitte M. Knudsen、Hartmut Lüddens、Frank Rösch

  DOI：10.1016/j.bmcl.2007.12.054

  日期：2008.2

  Radiochemical labeling of MDL 105725 using the secondary labeling precursor 2-[F-18] fluoroethyltosylate ([F-18] FETos) was carried out in yields of similar to 90% synthesizing [F-18] MHMZ in a speci. c activity of similar to 50 MBq/ nmol with a starting activity of similar to 3 GBq. Overall radiochemical yield including [F-18] FETos synthon synthesis, [F-18] fluoroalkylation and preparing the injectable [ 18 F] MHMZ solution was 42% within a synthesis time of similar to 100 min. The novel compound showed excellent speci. c binding to the 5-HT2A receptor (K-i = 9.0 nM) in vitro and promising in vivo characteristics. (C) 2007 Elsevier Ltd. All rights reserved.
• SULFURIC ACID MONO-[3-((1-(2-(4-FLUORO-PHENYL)-ETHYL]-PIPERIDIN-4-YL)-HYDROXY-METHYL)-2-METHOXY-PHENYL]ESTER
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1202967A2

  公开（公告）日：2002-05-08